Johnson & Johnson (BUE:JNJ) 6-1 Month Momentum % : 25.11% (As of Apr. 26, 2024)

View and export this data going back to . Start your Free Trial

What is Johnson & Johnson 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-26), Johnson & Johnson's 6-1 Month Momentum % is 25.11%.

The industry rank for Johnson & Johnson's 6-1 Month Momentum % or its related term are showing as below:

BUE:JNJ's 6-1 Month Momentum % is ranked better than
50.63% of 1114 companies
in the Drug Manufacturers industry
Industry Median: 1.805 vs BUE:JNJ: 25.11

Competitive Comparison of Johnson & Johnson's 6-1 Month Momentum %

For the Drug Manufacturers - General subindustry, Johnson & Johnson's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Johnson & Johnson's 6-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's 6-1 Month Momentum % falls into.

Johnson & Johnson (BUE:JNJ) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson (BUE:JNJ) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Johnson & Johnson 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Johnson & Johnson (BUE:JNJ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (BUE:JNJ) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

JNJ:USA JNJ:Peru JNJ:Mexico JNJ_KZ:Kazakhstan 1JNJ:Italy JNJd:UK 0R34:UK JNJ:Germany JNJ:Canada JNJB34:Brazil JNJ:Austria

Address

One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933

Website

https://www.jnj.com

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.